亲爱
发表于 2025-3-27 00:21:43
Subsequent Line Systemic Treatment Options for Advanced Renal Cell Carcinomaof care. Subsequently, the data for treatment options in second line and beyond has evolved. Recent phase 2/3 trials and retrospective analyses provide insights into treatment in the post-immunotherapy setting. It is crucial to compare the different types of treatments available to guide safe and ef
HEAVY
发表于 2025-3-27 02:22:24
http://reply.papertrans.cn/47/4688/468739/468739_32.png
Harbor
发表于 2025-3-27 06:46:48
Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcive radiation therapy (SAbR) at locations that were not previously feasible. While in the era of conventional protracted course radiation, renal cell cancer (RCC) was assessed to be radioresistant, and radiation therapy for RCC was even considered toxic, in the era of ablative hypofractionated radiat
antipsychotic
发表于 2025-3-27 09:28:19
Systemic Therapies for Advanced Non-Clear Cell Renal Cell Carcinoma RCC comprises a heterogeneous group of tumors—from the initial description of two subtypes in 1952 (clear cell and granular cell), the classification of kidney cancer has evolved to recognize a large variety of histological subtypes according to the World Health Organization (WHO), and over 50 gene
inhumane
发表于 2025-3-27 14:12:20
http://reply.papertrans.cn/47/4688/468739/468739_35.png
鸵鸟
发表于 2025-3-27 19:55:57
http://reply.papertrans.cn/47/4688/468739/468739_36.png
可商量
发表于 2025-3-27 22:29:16
Predictive Biomarkers in Advanced Renal Cell Carcinomas with advanced renal cell carcinoma. Although many of these biomarkers are not fully validated, initial investigations are promising. This chapter will explore our current knowledge of novel predictive biomarkers and discuss how they may be integrated into routine clinical use.
减去
发表于 2025-3-28 06:02:32
First-Line Systemic Treatment Options for Advanced Renal Cell Carcinomaapproved ICI combinations: ipilimumab/nivolumab, axitinib/pembrolizumab, axitinib/avelumab, cabozantinib/nivolumab, and lenvatinib/pembrolizumab. Challenges and approaches to therapeutic choices are also explored.
高度赞扬
发表于 2025-3-28 08:52:37
Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcition of SAbR with other local and systemic therapies is key in the optimal management of RCC patients. This chapter will discuss the rationale and available evidence for the integration and sequencing of SAbR with local and systemic therapies for RCC.
施加
发表于 2025-3-28 13:15:15
Radical Nephrectomy for Renal Cell Carcinomanefit. Management of RCC utilizing RN requires careful consideration of tumor size, location, local anatomy, and potential complication to select the proper technique and approach. This chapter reviews and describes relevant techniques, approaches, indications, outcomes, and considerations.